Avidity Partners 13F holdings, Q2 2023
Holdings as of June 30, 2023 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 93 US equity positions worth $2.9bn in its Q2 2023 13F filing. The largest position was BDX at 3.7% of the reported book, followed by KARUNA THERAPEUTICS INC and JAZZ. Against the Q1 2023 filing, it opened 12 new positions, added to 11 and reduced 26 among the top 50 holdings.
What did Avidity Partners own in Q2 2023? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2023 |
|---|---|---|---|---|---|---|---|
| 1 | BDX BECTON DICKINSON & CO | Healthcare | 3.7% | $105.1m | 398,050 | 38% | added |
| 2 | KARUNA THERAPEUTICS INC | 3.3% | $95.9m | 442,200 | 10% | added | |
| 3 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 3.0% | $87.1m | 702,778 | 4% | added |
| 4 | GEHC GE HEALTHCARE TECHNOLOGIES I | Healthcare | 3.0% | $84.9m | 1,045,400 | – | new |
| 5 | THC TENET HEALTHCARE CORP | Healthcare | 2.8% | $80.6m | 990,500 | -33% | reduced |
| 6 | ARGX ARGENX SE | Healthcare | 2.5% | $71.8m | 184,300 | -34% | reduced |
| 7 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 2.5% | $70.2m | 2,985,700 | -19% | reduced |
| 8 | SGRY SURGERY PARTNERS INC | Healthcare | 2.4% | $70.0m | 1,555,000 | -54% | reduced |
| 9 | ABBV ABBVIE INC | Healthcare | 2.4% | $69.8m | 518,400 | – | new |
| 10 | ARVN ARVINAS INC | Healthcare | 2.4% | $68.8m | 2,773,189 | -35% | reduced |
| 11 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 2.3% | $65.8m | 2,334,000 | -20% | reduced |
| 12 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 2.2% | $62.7m | 665,316 | -18% | reduced |
| 13 | LLY LILLY ELI & CO | Healthcare | 2.2% | $62.4m | 133,000 | – | new |
| 14 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 2.1% | $60.1m | 2,872,000 | -26% | reduced |
| 15 | UHS UNIVERSAL HLTH SVCS INC | Healthcare | 2.0% | $58.4m | 370,100 | -45% | reduced |
| 16 | BIO BIO RAD LABS INC | Healthcare | 2.0% | $57.9m | 152,600 | -31% | reduced |
| 17 | COR AMERISOURCEBERGEN CORP | Healthcare | 2.0% | $57.7m | 300,000 | 137% | added |
| 18 | PACB PACIFIC BIOSCIENCES CALIF IN | Healthcare | 2.0% | $57.7m | 4,337,400 | 14% | added |
| 19 | LEGN LEGEND BIOTECH CORP | Healthcare | 1.9% | $55.1m | 798,900 | -29% | reduced |
| 20 | BIIB BIOGEN INC | Healthcare | 1.7% | $49.6m | 174,000 | 35% | added |
| 21 | AKERO THERAPEUTICS INC | 1.7% | $47.9m | 1,025,000 | -58% | reduced | |
| 22 | CUREVAC N V | 1.6% | $44.8m | 4,300,000 | 21% | added | |
| 23 | ACHC ACADIA HEALTHCARE COMPANY IN | Healthcare | 1.5% | $43.8m | 550,000 | -53% | reduced |
| 24 | PCVX VAXCYTE INC | Healthcare | 1.5% | $43.7m | 875,000 | 72% | added |
| 25 | MCK MCKESSON CORP | Healthcare | 1.5% | $43.2m | 101,200 | – | new |
| 26 | APELLIS PHARMACEUTICALS INC | 1.5% | $42.7m | 468,700 | – | new | |
| 27 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 1.5% | $42.5m | 785,700 | -8% | reduced |
| 28 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 1.5% | $41.5m | 900,700 | -58% | reduced |
| 29 | PFE PFIZER INC | Healthcare | 1.4% | $41.0m | 1,117,467 | – | new |
| 30 | IMVT IMMUNOVANT INC | Healthcare | 1.4% | $39.6m | 2,085,000 | 100% | added |
| 31 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.4% | $39.2m | 545,000 | -12% | reduced |
| 32 | IMMUNOGEN INC | 1.3% | $37.7m | 1,997,800 | – | new | |
| 33 | ZTS ZOETIS INC | Healthcare | 1.3% | $37.4m | 217,000 | -47% | reduced |
| 34 | PROTHENA CORP PLC | 1.3% | $36.5m | 535,000 | -50% | reduced | |
| 35 | VIR VIR BIOTECHNOLOGY INC | Healthcare | 1.2% | $35.0m | 1,425,000 | -13% | reduced |
| 36 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 1.2% | $34.5m | 575,000 | -25% | reduced |
| 37 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 1.2% | $34.1m | 297,500 | -28% | reduced |
| 38 | ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 1.2% | $33.0m | 925,000 | -47% | reduced |
| 39 | BHVN BIOHAVEN LTD | Healthcare | 1.1% | $31.7m | 1,325,000 | -11% | reduced |
| 40 | RVMD REVOLUTION MEDICINES INC | Healthcare | 1.0% | $28.8m | 1,075,000 | -20% | reduced |
| 41 | PRVA PRIVIA HEALTH GROUP INC | Healthcare | 1.0% | $28.2m | 1,079,806 | – | new |
| 42 | PHAT PHATHOM PHARMACEUTICALS INC | 1.0% | $27.9m | 1,949,700 | -5% | reduced | |
| 43 | BAX BAXTER INTL INC | Healthcare | 1.0% | $27.6m | 604,700 | – | new |
| 44 | FUSION PHARMACEUTICALS INC | 0.9% | $26.6m | 5,700,000 | 0% | held | |
| 45 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 0.9% | $26.3m | 1,326,000 | 7% | added |
| 46 | 2655787D BLUEPRINT MEDICINES CORP | 0.9% | $26.2m | 415,000 | – | new | |
| 47 | EDIT EDITAS MEDICINE INC | Healthcare | 0.9% | $24.7m | 3,000,000 | – | new |
| 48 | VENTYX BIOSCIENCES INC | 0.8% | $22.7m | 692,500 | -64% | reduced | |
| 49 | NTRA NATERA INC | Healthcare | 0.7% | $21.1m | 432,900 | 73% | added |
| 50 | LNTH LANTHEUS HLDGS INC | Healthcare | 0.7% | $20.6m | 245,100 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.